|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
GLOBOCAN: Estimated cancer incidence,
mortality and prevalence worldwide in 2012. 2012, http://globocan.iarc.fr/Default.aspx.
|
|
3
|
Bray F, Ferlay J, Laversanne M, Brewster
DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E,
Swaminathan R, Antoni S, et al: Cancer Incidence in Five
Continents: Inclusion criteria, highlights from Volume X and the
global status of cancer registration. Int J Cancer. 137:2060–2071.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends - an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Worthley DL, Whitehall VL, Spring KJ and
Leggett BA: Colorectal carcinogenesis: Road maps to cancer. World J
Gastroenterol. 13:3784–3791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arends MJ: Pathways of colorectal
carcinogenesis. Appl Immunohistochem Mol Morphol. 21:97–102.
2013.PubMed/NCBI
|
|
8
|
Barrasa JI, Olmo N, Lizarbe MA and Turnay
J: Bile acids in the colon, from healthy to cytotoxic molecules.
Toxicol In Vitro. 27:964–977. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tariq K and Ghias K: Colorectal cancer
carcinogenesis: A review of mechanisms. Cancer Biol Med.
13:120–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tejpar S and Van Cutsem E: Molecular and
genetic defects in colorectal tumorigenesis. Best Pract Res Clin
Gastroenterol. 16:171–185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagahashi M, Wakai T, Shimada Y, Ichikawa
H, Kameyama H, Kobayashi T, Sakata J, Yagi R, Sato N, Kitagawa Y,
et al: Genomic landscape of colorectal cancer in Japan: Clinical
implications of comprehensive genomic sequencing for precision
medicine. Genome Med. 8:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu HY, Li C, Wang LM, Yang Y, Zhan ZL and
Zhang TZ: Establishment and characterization of a cell line
THC-8908 from human well differentiated colon adenocarcinoma. Chin
J Clin Oncol. 20:330–333. 1993.
|
|
14
|
Fu ZM: Establishment and characteristics
of a human colon adenocarcinoma cell line (SIC-8101). Chin J Clin
Oncol. 13:47–49. 1986.
|
|
15
|
Zhang ZX, Xu SH and Qian LJ: Establishment
and characterization of a cell line HR-8348 derived from human
poorly differentiated adenocarcinoma of rectum. Sci Sin B.
30:522–532. 1987.PubMed/NCBI
|
|
16
|
Zhang XZ: Establishment and
characterization of a cell line Hce-8693 from human
undifferentiated caecal adenocarcinoma. Zhonghua Zhong Liu Za Zhi.
11:413–415. 1989.In Chinese. PubMed/NCBI
|
|
17
|
Zheng XL, Zhou ZG, Gu J, Li HG, Lin L and
Deng YL: Establishment and characterization of a cell line HRC-99
from human rectal adenocarcinoma. World Chin J Digestology.
13:1510–1513. 2005.
|
|
18
|
Ding KF, Hu YT, Xiao Q, He JJ and Zheng S:
A cell line DXH-1 from human colon carcinoma and its application.
CN Patent CN201510631287.2. Filed September 29, 2015 issued
February 3, 2016.
|
|
19
|
Wang XY, Lai ZS, Yeung CM, Wang JD, Deng
W, Li HY, Han YJ, Kung HF, Jiang B and Lin MC: Establishment and
characterization of a new cell line derived from human colorectal
laterally spreading tumor. World J Gastroenterol. 14:1204–1211.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brattain MG, Brattain DE, Fine WD, Khaled
FM, Marks ME, Kimball PM, Arcolano LA and Danbury BH: Initiation
and characterization of cultures of human colonic carcinoma with
different biological characteristics utilizing feeder layers of
confluent fibroblasts. Oncodev Biol Med. 2:355–366. 1981.PubMed/NCBI
|
|
22
|
Peeh DM: Are primary cultures realistic
models of prostate cancer? J Cell Biochem. 91:185–195. 2004.
View Article : Google Scholar
|
|
23
|
Capper D, Voigt A, Bozukova G, Ahadova A,
Kickingereder P, von Deimling A, von Knebel Doeberitz M and Kloor
M: BRAF V600E-specific immunohistochemistry for the exclusion of
Lynch syndrome in MSI-H colorectal cancer. Int J Cancer.
133:1624–1630. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aaltonen LA, Peltomäki P, Leach FS,
Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J,
Hamilton SR, et al: Clues to the pathogenesis of familial
colorectal cancer. Science. 260:812–816. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ionov Y, Peinado MA, Malkhosyan S, Shibata
D and Perucho M: Ubiquitous somatic mutations in simple repeated
sequences reveal a new mechanism for colonic carcinogenesis.
Nature. 363:558–561. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parsons R, Li GM, Longley MJ, Fang WH,
Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B
and Modrich P: Hypermutability and mismatch repair deficiency in
RER+ tumor cells. Cell. 75:1227–1236. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsukamoto Y, Fumoto S, Noguchi T,
Yanagihara K, Hirashita Y, Nakada C, Hijiya N, Uchida T, Matsuura
K, Hamanaka R, et al: Expression of DDX27 contributes to
colony-forming ability of gastric cancer cells and correlates with
poor prognosis in gastric cancer. Am J Cancer Res. 5:2998–3014.
2015.PubMed/NCBI
|
|
28
|
Ercan D, Choi HG, Yun CH, Capelletti M,
Xie T, Eck MJ, Gray NS and Jänne PA: EGFR mutations and resistance
to irreversible pyrimidine based EGFR receptors. Clin Cancer Res.
21:3913–3923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mayr C, Wagner A, Stoecklinger A, Jakab M,
Illig R, Berr F, Pichler M, Di Fazio P, Ocker M, Neureiter D, et
al: 3-Deazaneplanocin A may directly target putative cancer stem
cells in biliary tract cancer. Anticancer Res. 35:4697–4705.
2015.PubMed/NCBI
|
|
30
|
Hua G, Lv X, He C, Remmenga SW, Rodabough
KJ, Dong J, Yang L, Lele SM, Yang P, Zhou J, et al: YAP induces
high-grade serous carcinoma in fallopian tube secretory epithelial
cells. Oncogene. 35:2247–2265. 2016. View Article : Google Scholar :
|
|
31
|
Ukaji T, Lin Y, Banno K, Okada S and
Umezawa K: Inhibition of IGF-1 mediated cellular migration and
invasion by migracin A in ovarian clear cell carcinoma cells. PLoS
One. 10:e01376632015. View Article : Google Scholar
|
|
32
|
Bon H, Wadhwa K, Schreiner A, Osborne M,
Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R,
Ahmed AA, et al: Salt-inducible kinase 2 regulates mitotic
progression and transcription in prostate cancer. Mol Cancer Res.
13:620–635. 2015. View Article : Google Scholar :
|
|
33
|
Kim T, Jeon YJ, Cui R, Lee JH, Peng Y, Kim
SH, Tili E, Alder H and Croce CM: Role of MYC-regulated long
noncoding RNAs in cell cycle regulation and tumorigenesis. J Natl
Cancer Inst. 107:dju5052015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dou J and Gu N: Emerging strategies for
the identification and targeting of cancer stem cells. Tumour Biol.
31:243–253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Varadhachary GR, Abbruzzese JL and Lenzi
R: Diagnostic strategies for unknown primary cancer. Cancer.
100:1776–1785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moll R, Löwe A, Laufer J and Franke WW:
Cytokeratin 20 in human carcinomas. A new histodiagnostic marker
detected by monoclonal antibodies. Am J Pathol. 140:427–447.
1992.PubMed/NCBI
|
|
39
|
Loy TS and Calaluce RD: Utility of
cytokeratin immunostaining in separating pulmonary adenocarcinomas
from colonic adeno-carcinomas. Am J Clin Pathol. 102:764–767. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wauters CC, Smedts F, Gerrits LG, Bosman
FT and Ramaekers FC: Keratins 7 and 20 as diagnostic markers of
carcinomas metastatic to the ovary. Hum Pathol. 26:852–855. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chu P, Wu E and Weiss LM: Cytokeratin 7
and cytokeratin 20 expression in epithelial neoplasms: A survey of
435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Park SY, Kim HS, Hong EK and Kim WH:
Expression of cytokeratins 7 and 20 in primary carcinomas of the
stomach and colorectum and their value in the differential
diagnosis of metastatic carcinomas to the ovary. Hum Pathol.
33:1078–1085. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Imai Y, Yamagishi H, Fukuda K, Okamura T,
Ono Y, Ban S, Inoue T and Ueda Y: Expression of cytokeratin 20
indicates invasive histological phenotype in poorly differentiated
colorectal adenocarcinoma. Anticancer Res. 34:159–167.
2014.PubMed/NCBI
|
|
44
|
Bayrak R, Haltas H and Yenidunya S: The
value of CDX2 and cytokeratins 7 and 20 expression in
differentiating colorectal adenocarcinomas from extraintestinal
gastrointestinal adeno-carcinomas: Cytokeratin
7−/20+ phenotype is more specific than CDX2
antibody. Diagn Pathol. 7:92012. View Article : Google Scholar
|
|
45
|
Hinoi T, Tani M, Lucas PC, Caca K, Dunn
RL, Macri E, Loda M, Appelman HD, Cho KR and Fearon ER: Loss of
CDX2 expression and microsatellite instability are prominent
features of large cell minimally differentiated carcinomas of the
colon. Am J Pathol. 159:2239–2248. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kaimaktchiev V, Terracciano L, Tornillo L,
Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M,
Sauter G, et al: The homeobox intestinal differentiation factor
CDX2 is selectively expressed in gastrointestinal adenocarcinomas.
Mod Pathol. 17:1392–1399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jasperson KW, Tuohy TM, Neklason DW and
Burt RW: Hereditary and familial colon cancer. Gastroenterology.
138:2044–2058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Strate LL and Syngal S: Hereditary
colorectal cancer syndromes. Cancer Causes Control. 16:201–213.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Macrae F, Harris M, Massimo R and Alberto
M: Re: Revised Bethesda Guidelines for hereditary nonpolyposis
colorectal cancer (Lynch syndrome) and microsatellite instability.
J Natl Cancer Inst. 97:936–937; author reply 937-938. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Senapati S, Sharma P, Bafna S, Roy HK and
Batra SK: The MUC gene family: Their role in the diagnosis and
prognosis of gastric cancer. Histol Histopathol. 23:1541–1552.
2008.PubMed/NCBI
|
|
51
|
Williams SJ, McGuckin MA, Gotley DC, Eyre
HJ, Sutherland GR and Antalis TM: Two novel mucin genes
down-regulated in colorectal cancer identified by differential
display. Cancer Res. 59:4083–4089. 1999.PubMed/NCBI
|
|
52
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View Article : Google Scholar
|
|
53
|
Packer LM, Williams SJ, Callaghan S,
Gotley DC and McGuckin MA: Expression of the cell surface mucin
gene family in adenocarcinomas. Int J Oncol. 25:1119–1126.
2004.PubMed/NCBI
|
|
54
|
Matsuyama T, Ishikawa T, Mogushi K,
Yoshida T, Iida S, Uetake H, Mizushima H, Tanaka H and Sugihara K:
MUC12 mRNA expression is an independent marker of prognosis in
stage II and stage III colorectal cancer. Int J Cancer.
127:2292–2299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yin BW and Lloyd KO: Molecular cloning of
the CA125 ovarian cancer antigen: Identification as a new mucin,
MUC16. J Biol Chem. 276:27371–27375. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yin BW, Dnistrian A and Lloyd KO: Ovarian
cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J
Cancer. 98:737–740. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang B, Liang XL, Gao HY, Ye LS and Wang
YG: Models of logistic regression analysis, support vector machine,
and back-propagation neural network based on serum tumor markers in
colorectal cancer diagnosis. Genet Mol Res. May 13–2016.Epub ahead
of print. View Article : Google Scholar
|
|
59
|
Skaaby T, Husemoen LL, Thyssen JP,
Meldgaard M, Thuesen BH, Pisinger C, Jørgensen T, Carlsen K,
Johansen JD, Menné T, et al: Filaggrin loss-of-function mutations
and incident cancer: A population-based study. Br J Dermatol.
171:1407–1414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang M, Li X, Zhang J, Yang Q, Chen W, Jin
W, Huang YR, Yang R and Gao WQ: AHNAK2 is a novel prognostic marker
and oncogenic protein for clear cell renal cell carcinoma.
Theranostics. 7:1100–1113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lu D, Wang J, Shi X, Yue B and Hao J:
AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Oncotarget. 8:31775–31784. 2017.PubMed/NCBI
|
|
62
|
Wen L, Zhu C, Zhu Z, Yang C, Zheng X, Liu
L, Zuo X, Sheng Y, Tang H, Liang B, et al: Exome-wide association
study identifies four novel loci for systemic lupus erythematosus
in Han Chinese population. Ann Rheum Dis. 77:4172018. View Article : Google Scholar
|
